This websites contains videos from YouTube. This company uses
cookies (third party cookies). If you do not want them to use these
cookies, you can indicate so here. However, this does mean that you
will not be able to watch videos on this website. We also make use
of our own cookies in order to improve our website. We don't share
our data with other parties. Which cookies are involved?
user experience. If you do not want to accept these cookies,
indicate so here. Which cookies are involved?
Research led by Lisette Rozeman was selected by the American
Society of Clinical Oncology for inclusion in the Clinical Cancer
Advances 2020, which highlights the most impactful research
advances of the past year.
High-dose chemotherapy in high-risk breast cancer shows improved survival in 20-year follow-up
A follow-up study after 20
years shows that the survival rate for women with breast cancer and
ten or more affected lymph nodes in the armpit is 15% higher after
high-dose chemotherapy than after the conventional dose. Moreover,
the patients did not show an increase in secondary cancers or
serious cardiovascular diseases. The follow-up study, coordinated
by Tessa Steenbruggen (Netherlands Cancer Institute) and Lars
Steggink (UMCG), was published in JAMA Oncology at January 30.